FR12 Alfatradiol Finasteride Spray: Why the Formula Uses Two DHT-Supporting Ingredients

The FR12 alfatradiol finasteride spray combines two ingredients that the manufacturer places within the formula’s DHT-support strategy. Finasteride is an established 5-alpha-reductase inhibitor. Alfatradiol—also known as 17α-estradiol—has been studied as a topical treatment intended primarily to slow or stabilise androgen-related hair loss.

The live Follics FR12 Minoxidil 12% and Finasteride Spray page confirms that the product contains 12% Minoxidil Sulphate, Finasteride USP, alfatradiol, AC Retinol Liposomes, adenosine, Procapil, azelaic acid, Procyanidin B2, copper peptide GHK-Cu and Liposphere technology. It positions the spray for both the vertex and hairline.

The important evidence limitation for FR12 alfatradiol finasteride spray is that the public page does not state:

• Finasteride concentration.
• Alfatradiol concentration.
• Milligrams of either ingredient per pump.
• A clinical trial testing the finished FR12 formula.
• A direct study proving that finasteride and alfatradiol provide additive or synergistic benefit when combined in FR12.
• FR12-specific plasma finasteride or serum-DHT measurements.

Therefore, the two ingredients can be explained as mechanistically related components, but the finished combination cannot be called clinically proven to work better than finasteride alone.

Direct Answer

Why does FR12 contain both alfatradiol and finasteride?

The formula appears designed to combine:

• Finasteride: a direct inhibitor of 5-alpha-reductase, the enzyme involved in converting testosterone to dihydrotestosterone.
• Alfatradiol: a topical 17α-estradiol ingredient that has been studied mainly for slowing or stabilising androgenetic hair loss.
• Minoxidil sulphate: the formula’s high-strength growth-stimulation component.
• Supporting ingredients: components positioned for scalp, follicle and delivery support.

Independent evidence supports topical finasteride as a treatment concept in male androgenetic alopecia. Alfatradiol also has human clinical evidence, but much of it comes from women using approximately 0.025% topical solutions. In a comparative trial, alfatradiol largely stabilised hair parameters while minoxidil produced clearer increases in density and cumulative hair thickness.

No published trial identified for this article tested:

12% Minoxidil Sulphate + unspecified topical finasteride + unspecified alfatradiol in the complete FR12 vehicle.

The correct conclusion for FR12 alfatradiol finasteride spray is:

FR12 combines two ingredients associated with androgen or DHT-focused hair-loss care, but their combined benefit inside FR12 remains a manufacturer-led formulation rationale rather than independently proven synergy.

What the FR12 Product Page Actually Confirms

The current FR12 alfatradiol finasteride spray page confirms the following formula and directions.

Formula components

• Minoxidil Sulphate 12%.
• Finasteride USP.
• Alfatradiol.
• AC Retinol Liposomes.
• Adenosine.
• Procapil blend.
• Azelaic acid.
• Procyanidin B2.
• Copper peptide GHK-Cu.
• Liposphere technology.

Treatment-area positioning

The page positions FR12 for:

• Vertex thinning.
• Hairline thinning.
• Broader patterned thinning affecting the scalp.

Application directions

The live page instructs users to:

1. Dispense five pumps.
2. Apply twice daily.
3. Focus on hair-loss or thinning areas.
4. Massage for two to four minutes.
5. Wash the hands afterwards.
6. Leave the product on for four or more hours.
7. Avoid using more than directed.

Storage directions

FR12 should be kept:

• In a cool, dry place.
• Away from direct sunlight.
• Protected from freezing.
• Protected from excessive heat.

Missing public specifications

The page does not display:

These FR12 alfatradiol finasteride spray gaps must be resolved from the physical bottle, carton, leaflet or manufacturer documentation before publication

FR12 Alfatradiol Finasteride Spray: What “Dual DHT Support” Means

Androgenetic alopecia involves progressive follicle miniaturisation in genetically susceptible scalp areas.

Dihydrotestosterone, or DHT, is produced when 5-alpha-reductase converts testosterone into a more potent androgen. Finasteride inhibits this enzyme, particularly type II and type III activity according to the FR12 product description and official finasteride pharmacology.

The FR12 alfatradiol finasteride spray formula places both finasteride and alfatradiol within the broader objective of reducing androgen-related pressure on vulnerable follicles.

That does not mean they have identical roles.

Simplified ingredient model

Testosterone

     │

     │  5-alpha-reductase

     ▼

Dihydrotestosterone

     │

     ▼

Androgen-sensitive follicle miniaturisation

Finasteride:

Directly inhibits 5-alpha-reductase

Alfatradiol:

Used topically as an androgen-related

hair-loss stabilisation ingredient

FR12:

Combines both with Minoxidil Sulphate

and additional scalp-support ingredients

The diagram is a conceptual explanation of FR12 alfatradiol finasteride spray, not proof of an FR12-specific clinical interaction

What Is Finasteride Doing in FR12?

In FR12 alfatradiol finasteride spray, finasteride is the more established DHT-targeting ingredient in the formula.

Its primary pharmacological action is inhibition of 5-alpha-reductase, reducing conversion of testosterone into DHT.

Topical-finasteride research has shown that a carefully designed spray formulation can improve hair count in men with androgenetic alopecia. In a phase III study, the tested topical spray produced significantly greater hair-count improvement than placebo and a result numerically similar to oral finasteride at 24 weeks. Maximum plasma finasteride concentrations were more than 100 times lower with the studied topical product, while serum DHT still fell by an average of 34.5%.

This evidence demonstrates two important points:

1. Topical finasteride can have clinically meaningful scalp effects.
2. Topical finasteride can still produce measurable systemic hormonal effects.

Why the study cannot be assigned directly to FR12

The phase III trial tested a specific metered formulation with a defined dose and delivery system.

FR12’s public page does not disclose:

• Finasteride concentration.
• Finasteride milligrams per pump.
• Total daily finasteride exposure.
• Plasma-finasteride concentration.
• Serum-DHT reduction.
• Whether its spray calibration matches the studied product.

Therefore, FR12 alfatradiol finasteride spray cannot claim the trial’s exact efficacy, absorption or safety findings as its own.

What Is Alfatradiol?

Alfatradiol is another name used for 17α-estradiol.

It is structurally related to estradiol but is not the same as the more strongly estrogenic 17β-estradiol normally discussed in reproductive physiology.

In FR12 alfatradiol finasteride spray, alfatradiol is included against a background of topical use aimed at slowing androgen-dependent hair loss.

The FR12 manufacturer states that alfatradiol inhibits 5-alpha-reductase and also attributes ion-channel activity to the ingredient. However, the public FR12 page does not provide the alfatradiol concentration, supporting study or finished-product mechanism data.

Evidence-safe description

Alfatradiol should be described as:

A topical 17α-estradiol ingredient with clinical evidence suggesting possible stabilisation or deceleration of androgenetic hair loss.

It should not be described as:

• A proven replacement for finasteride.
• A guaranteed DHT blocker.
• A powerful estrogen-free finasteride equivalent.
• A clinically proven regrowth ingredient in FR12.
• An ingredient proven to eliminate systemic finasteride risk.
• A hormone that is biologically inactive.

What Do Human Alfatradiol Studies Show?

Controlled study of 17α-estradiol

An older controlled, randomised, double-blind study included 51 patients with androgenetic alopecia and increased hair shedding.

After at least six months:

• Fewer people in the treated group experienced worsening than in the control group.
• The investigators reported possible value in reducing androgenetic hair loss.
• No new-hair regrowth was demonstrated.

For FR12 alfatradiol finasteride spray, this supports a stabilisation interpretation more strongly than a dramatic-regrowth claim.

Alfatradiol versus 2% minoxidil

A later trial randomised women to either:

• 2% minoxidil twice daily, or
• 0.025% alfatradiol once daily.

After six months:

• Minoxidil significantly increased hair density and cumulative hair thickness.
• Hair-growth parameters remained nearly unchanged with alfatradiol.
• Researchers concluded that alfatradiol primarily slowed or stabilised loss, while minoxidil induced clearer growth-related changes.

Open-label alfatradiol study

An open-label study of 53 Korean women using 0.025% 17α-estradiol once daily reported increases in hair count and diameter over eight months. However, there was no placebo or active comparator group, limiting how confidently the improvement can be attributed to alfatradiol.

What these studies do not prove for FR12 alfatradiol finasteride spray

They do not establish:

• Efficacy in men using FR12.
• The correct alfatradiol concentration for FR12.
• Twice-daily alfatradiol safety.
• Benefit when combined with high-strength minoxidil sulphate.
• Additive benefit with topical finasteride.
• FR12-specific DHT reduction.
• FR12-specific regrowth percentages.
• Long-term hormonal safety.

Much of the alfatradiol evidence comes from women and from 0.025% formulations. FR12 is currently listed in the Men category, making direct extrapolation especially uncertain.

Is Alfatradiol as Strong as Finasteride?

For FR12 alfatradiol finasteride spray, the available evidence does not support treating the two ingredients as equivalent.

A retrospective study in 119 postmenopausal women compared:

• Topical 0.5% finasteride with 2% minoxidil.
• Topical 0.05% 17α-estradiol with 2% minoxidil.

Both groups improved, but the finasteride-containing regimen produced significantly greater photographic improvement at six months and at the longer follow-up. The study was retrospective and involved women, but it reinforces that finasteride and alfatradiol should not be described as interchangeable.

Practical interpretation

Why Might a Formula Include Both?

There are several possible formulation reasons for FR12 alfatradiol finasteride spray.

1. Different evidence histories

Finasteride has stronger evidence for DHT reduction and male-pattern hair loss.

Alfatradiol has a history of topical use focused on stabilisation.

A manufacturer may combine them to create a broader androgen-focused formula.

2. Different proposed biological actions

Finasteride has a clearly defined enzyme-inhibition pathway.

Alfatradiol has been proposed to influence local androgen metabolism, but its clinical mechanism remains less firmly established.

3. Combination positioning

FR12 is presented as more than a high-strength minoxidil formula.

Including both ingredients distinguishes it from the Follics FR10 Minoxidil 10% treatment, whose current page does not list finasteride or alfatradiol.

4. Stabilisation plus stimulation concept

The intended formula logic appears to be:

• Minoxidil sulphate for growth stimulation.
• Finasteride for direct DHT reduction.
• Alfatradiol for additional androgen-related stabilisation.
• Supporting ingredients for scalp and follicle positioning.

Important limitation

This is an interpretation of the FR12 alfatradiol finasteride spray formula structure

It is not evidence that:

• Two DHT-support ingredients always outperform one.
• Alfatradiol prevents finasteride side effects.
• The combination allows a lower finasteride dose.
• Finasteride and alfatradiol act synergistically.
• FR12 works better than another clinically studied treatment.
• More ingredients automatically improve results.

Is There a Clinical Trial of Alfatradiol and Finasteride Together?

No directly applicable trial was identified for the exact FR12 alfatradiol finasteride spray combination.

Research exists for:

• Topical finasteride alone.
• Topical finasteride with minoxidil.
• Alfatradiol alone.
• Alfatradiol with minoxidil.
• Finasteride versus alfatradiol in different combination regimens.

But no identified study tested the complete FR12 formula with:

• 12% Minoxidil Sulphate.
• Finasteride at FR12’s undisclosed concentration.
• Alfatradiol at FR12’s undisclosed concentration.
• AC Retinol Liposomes.
• GHK-Cu.
• Adenosine.
• Procapil.
• Azelaic acid.
• Procyanidin B2.
• The FR12 Liposphere vehicle.

Evidence from finasteride-plus-minoxidil studies

A small randomised study of 40 men found that topical 0.25% finasteride combined with 3% minoxidil improved hair measures more than 3% minoxidil alone over 24 weeks.

Another pilot trial assessed 0.25% topical finasteride with 5% minoxidil against the ingredients used separately.

These studies provide related evidence for FR12 alfatradiol finasteride spray, but they specifically support investigation of topical finasteride-plus-minoxidil combinations.

They do not establish:

• FR12’s finasteride dose.
• FR12’s minoxidil-sulphate behaviour.
• Alfatradiol’s added contribution.
• Safety of the full twice-daily FR12 formula.
• FR12’s systemic exposure.

Evidence Hierarchy for the FR12 Dual DHT-Support Formula

Level 1 — Verified FR12 product information

The official page confirms:

• 12% Minoxidil Sulphate.
• Finasteride USP.
• Alfatradiol.
• Full-scalp positioning.
• Five pumps twice daily.
• Two-to-four-minute massage.
• Four-hour or longer leave-in period.

Level 2 — Randomised topical-finasteride evidence

A phase III topical-finasteride spray improved hair count versus placebo in adult men and produced lower plasma exposure than oral finasteride, while still reducing serum DHT.

Level 3 — Alfatradiol clinical evidence

Controlled and comparative studies suggest that topical alfatradiol may slow or stabilise androgenetic hair loss, although its growth effects have generally been less convincing than minoxidil.

Level 4 — Related combination studies

Topical finasteride-plus-minoxidil and alfatradiol-plus-minoxidil combinations have been studied in other concentrations and populations.

Level 5 — FR12-specific uncertainty

The public evidence for FR12 alfatradiol finasteride spray does not provide:

• An FR12 randomised trial.
• FR12 hair-count data.
• FR12 response rates.
• FR12 systemic finasteride levels.
• FR12 serum-DHT reduction.
• FR12 alfatradiol concentration.
• FR12 finasteride concentration.
• Proof of additive benefit from combining both.
• Long-term FR12 safety.
• FR12 fertility data.
• FR12 pregnancy-transfer data.

Manufacturer Claims Versus Independent Evidence

Concentration and Unit Verification

The public page confirms only one numerical active concentration:

• Minoxidil Sulphate 12%.

It does not provide numerical concentrations for:

• Finasteride.
• Alfatradiol.
• Azelaic acid.
• GHK-Cu.
• Retinol.
• Adenosine.

Why this matters

The effects of ingredients in FR12 alfatradiol finasteride spray depend on:

• Concentration.
• Volume applied.
• Application frequency.
• Vehicle.
• Scalp condition.
• Total treated area.
• Barrier disruption.
• Systemic absorption.

Two products can both list “topical finasteride” while delivering very different daily exposures.

Minoxidil sulphate calculation

If the physical label confirms that 12% is expressed as w/v, the conventional calculation would be:

12 grams per 100 mL

= 12,000 milligrams per 100 mL

= 120 milligrams per mL

However, the public page does not explicitly display “12% w/v,” and it does not state the volume dispensed by five pumps.

Do not calculate:

• Milligrams of minoxidil sulphate per application.
• Milligrams of finasteride per application.
• Milligrams of alfatradiol per application.

until pump calibration and concentration units are confirmed.

How Is FR12 Different From FIN25?

Regrowth Labs FIN25 topical finasteride solution is positioned around Finasteride USP 0.25% in a propanediol-based scalp solution. Its live page does not list minoxidil or alfatradiol.

FR12 alfatradiol finasteride spray is a broader multi-active formulation containing:

• High-strength Minoxidil Sulphate.
• Finasteride.
• Alfatradiol.
• Several supporting ingredients.

This table explains product positioning rather than declaring one superior.

How Is FR12 Different From FR10?

The live Follics FR10 Minoxidil 10% treatment page lists:

• Minoxidil USP 10%.
• Bimatoprost.
• Adenosine.
• Procapil.
• Azelaic acid.
• Procyanidin B2.
• Biotin.
• Vitamin B complex.

It does not list finasteride or alfatradiol.

The main formula distinction is therefore:

• FR10: High-strength minoxidil formulation without listed finasteride.
• FR12: High-strength minoxidil-sulphate formulation with finasteride and alfatradiol.

A buyer should not choose based only on the number 10 or 12.

The clinically important differences include:

• Active ingredient type.
• DHT-targeting exposure.
• Pregnancy-transfer precautions.
• Side-effect profile.
• Scalp tolerance.
• Product-specific evidence.
• Medical history.

Who Might Consider FR12?

FR12 alfatradiol finasteride spray may deserve professional consideration for an adult man who:

• Has a confirmed diagnosis of androgenetic alopecia.
• Has patterned thinning affecting the hairline, vertex or both.
• Has discussed high-strength topical minoxidil.
• Understands that the formula also contains topical finasteride.
• Understands that alfatradiol evidence is more limited.
• Can follow five pumps twice daily.
• Can maintain two four-hour leave-in windows.
• Can prevent transfer to others.
• Has reviewed sexual, reproductive and PSA considerations.
• Is not using another finasteride or dutasteride product without medical supervision.
• Has checked the complete physical label.
• Accepts that FR12-specific trial data are not displayed.

FR12 should not be positioned as the automatic next step for every person who has not responded quickly to lower-strength minoxidil.

Who Should Not Self-Start FR12?

Medical review is particularly important for:

• Anyone without a confirmed hair-loss diagnosis.
• People with sudden or patchy hair loss.
• People with an inflamed, painful or infected scalp.
• First-time minoxidil users.
• People with heart disease.
• People with low blood pressure.
• People taking blood-pressure medicines.
• People already using oral or topical finasteride.
• People using dutasteride.
• Men trying to conceive.
• Men with fertility concerns.
• Men with sexual dysfunction.
• Men with depression or significant mood symptoms.
• Anyone undergoing PSA testing.
• Women who are pregnant or may become pregnant.
• Breastfeeding individuals.
• Children and teenagers.
• People planning microneedling or a scalp procedure.

Pregnancy and Transfer Precautions

Finasteride can pose a risk to development of a male fetus.

Official oral-finasteride labelling warns that pregnant or potentially pregnant women should not handle crushed or broken tablets because finasteride may be absorbed through the skin.

FR12 alfatradiol finasteride spray is a liquid applied directly to the scalp.

Although oral-tablet handling instructions are not a product-specific FR12 study, they support conservative precautions for a wet finasteride-containing topical solution.

Prevent transfer through:

• Unwashed hands.
• Wet scalp contact.
• Shared pillows.
• Towels.
• Caps.
• Helmets.
• Head coverings.
• Combs contacting wet solution.
• Spilled product.
• A leaking bottle.
• Children or pets touching the treated area.

Safer handling routine

1. Apply the product yourself where possible.
2. Use only the stated five pumps.
3. Wash hands immediately.
4. Clean spills.
5. Allow full drying.
6. Avoid wet-scalp contact with another person.
7. Store the bottle securely.
8. Do not allow a pregnant person to handle the liquid.

If accidental exposure occurs

• Wash exposed skin promptly with soap and water.
• Follow the physical FR12 emergency instructions.
• Seek professional advice after meaningful pregnancy exposure.
• Do not continue using a leaking bottle.

The physical FR12 packaging must be checked for product-specific pregnancy wording before publication.

Sexual, Reproductive and Mood Considerations

Official finasteride 1mg labelling identifies decreased libido, erectile dysfunction and ejaculation disorder among adverse reactions reported more often than placebo.

Post-marketing reports also include:

• Persistent sexual dysfunction.
• Testicular pain.
• Male infertility or poor semen quality.
• Depression.
• Breast tenderness or enlargement.
• Hypersensitivity reactions.

These data come from oral finasteride.

They do not provide an FR12 adverse-event rate.

However, topical finasteride can produce systemic exposure and serum-DHT reduction, so the class-related concerns should not be dismissed.

Seek medical advice for:

• New erectile difficulty.
• Reduced libido.
• Ejaculation changes.
• Testicular pain.
• Fertility concerns.
• Breast pain.
• Breast enlargement.
• A breast lump or nipple discharge.
• New or worsening depression.
• Any persistent or distressing symptom.

PSA Testing

Finasteride can lower prostate-specific antigen.

Official oral-finasteride data show a reduction in mean PSA among younger men using 1mg treatment. Finasteride use should be disclosed before PSA interpretation.

FR12-specific PSA data are not available publicly.

Because FR12 contains topical finasteride and systemic absorption cannot be ruled out:

Tell the doctor or laboratory that you use FR12 before a PSA test or prostate assessment.

Do not assume that topical exposure is irrelevant.

Minoxidil-Related Safety Still Matters

FR12 combines finasteride and alfatradiol with 12% Minoxidil Sulphate.

Standard topical-minoxidil labels advise medical caution in people with heart disease and instruct users to stop and seek advice for:

• Chest pain.
• Rapid heartbeat.
• Faintness.
• Dizziness.
• Sudden unexplained weight gain.
• Swelling of hands or feet.
• Persistent scalp irritation.
• Unwanted facial hair.

These warnings come from standard lower-strength minoxidil products.

They should be treated as a minimum safety framework—not a complete FR12-specific adverse-effect list.

Scalp Irritation Risk

FR12 alfatradiol finasteride spray contains several active and supporting ingredients

Possible local concerns include:

• Redness.
• Burning.
• Itching.
• Dryness.
• Scaling.
• Contact dermatitis.
• Folliculitis-like bumps.
• Runoff toward the face.
• Eye irritation.
• Unwanted hair growth outside the scalp.

A multi-active formula can make it harder to identify which ingredient caused a reaction.

Stop use and seek advice when:

• Burning is severe.
• Redness persists.
• Swelling develops.
• Blisters appear.
• The rash spreads beyond the scalp.
• Facial swelling occurs.
• Breathing becomes difficult.
• The eyes are exposed and remain painful.
• Systemic symptoms appear.

FR12 and Microneedling

Do not apply FR12 to freshly microneedled, bleeding or damaged scalp unless a qualified clinician has provided a specific protocol.

Microneedling may alter:

• Finasteride absorption.
• Minoxidil-sulphate absorption.
• Alfatradiol exposure.
• Retinol-related irritation.
• Systemic exposure.
• Runoff.
• Adverse-effect risk.

The public FR12 page does not provide a microneedling protocol.

FR12 Application Routine

The verified directions are:

Dry and intact scalp

        │

        ▼

Dispense five pumps

        │

        ▼

Target prescribed thinning areas

        │

        ▼

Massage for two to four minutes

        │

        ▼

Wash hands immediately

        │

        ▼

Keep treatment on for four or more hours

The product page directs twice-daily use and states that using more will not increase effectiveness.

Do not:

• Add extra pumps for a larger crown.
• Apply a separate full dose to the hairline and vertex.
• Double after a missed application.
• Use oral finasteride at the same time without clinical direction.
• Layer FIN25 over FR12.
• Apply on wet or broken scalp.
• Apply immediately before swimming.
• Wash the scalp during the four-hour window.
• Allow the wet product to contact another person.

Can FR12 Be Combined With FIN25 or Finasteride Tablets?

Do not combine finasteride-containing treatments independently.

FR12 already contains finasteride.

Adding:

• FIN25.
• Oral finasteride.
• FR16.
• Another compounded finasteride spray.

could increase total exposure.

A clinician would need to consider:

• Total finasteride dose.
• Serum-DHT effects.
• Sexual adverse effects.
• Fertility plans.
• PSA testing.
• Scalp irritation.
• Other medicines.
• Whether combination use has any justified benefit.

More DHT suppression is not automatically better or safer.

Can FR12 Be Combined With Dutasteride?

This article intentionally does not compare finasteride and dutasteride.

Do not combine FR12 with:

• Oral dutasteride.
• D5a.
• 7HP.
• Another topical dutasteride product.

unless a qualified clinician has reviewed the total 5-alpha-reductase-inhibitor exposure.

UAE Routine Considerations

Workdays

Apply only when the four-hour leave-in period can be protected.

Avoid applying immediately before:

• A helmet.
• A tight cap.
• Heavy outdoor work.
• A midday shower.
• Swimming.
• A hot gym session.

Gym routines

The more controlled sequence is:

Workout → shower → dry scalp → FR12 → hand washing → four-hour leave-in.

Bedtime

Apply early enough to:

• Massage properly.
• Wash the hands.
• Let the product dry.
• Avoid wet-pillow transfer.

UAE heat

The product page instructs users to protect FR12 from direct sunlight, freezing and excessive heat. Do not leave it in a parked vehicle.

Travel

Keep FR12:

• In original packaging.
• With its readable label.
• Protected from leakage.
• Away from wet gym items.
• Within the physical-label storage requirements.
• Away from children.

Product-Label Verification Checklist

Product identity

• Product name states Follics FR12.
• Minoxidil Sulphate 12% is listed.
• Finasteride USP is listed.
• Alfatradiol is listed.
• Bottle and carton match.
• Batch and expiry are visible.

Concentrations

• Minoxidil percentage unit is confirmed.
• Finasteride concentration is confirmed.
• Alfatradiol concentration is confirmed.
• Azelaic-acid concentration is checked.
• Retinol concentration is checked.
• GHK-Cu concentration is checked.

Dose

• Five pumps are confirmed.
• Volume per pump is confirmed.
• Twice-daily use is confirmed.
• Maximum daily amount is confirmed.
• Missed-dose instructions are checked.

Application

• Dry-scalp wording is checked.
• Massage time is confirmed.
• Four-hour leave-in is confirmed.
• Drying time is checked.
• Shower and swimming instructions are checked.
• Hairline and vertex directions are checked.

Safety

• Pregnancy warning is checked.
• Transfer precautions are checked.
• Finasteride adverse effects are checked.
• Minoxidil cardiovascular warnings are checked.
• PSA disclosure wording is checked.
• Fertility warning is checked.
• Broken-skin warning is checked.
• Eye-contact instructions are checked.

Ingredients and storage

• Full inactive ingredients are listed.
• Alcohol content is checked.
• Propylene-glycol content is checked.
• Allergen information is checked.
• Storage instructions are confirmed.
• Container-closure instructions are checked.

For missing concentrations or conflicting instructions, contact Hims & Hers UAE before using the product.

Buyer Decision Checklist

FR12 may deserve further medical consideration when:

• Male-pattern hair loss has been professionally diagnosed.
• Hairline or vertex thinning is present.
• High-strength minoxidil has been medically discussed.
• The user understands that FR12 contains finasteride.
• The user understands the limited alfatradiol evidence.
• The physical label provides all concentrations.
• Five pumps twice daily can be followed.
• Two four-hour leave-in windows are realistic.
• Pregnancy-transfer precautions can be maintained.
• PSA testing and fertility plans have been discussed.
• No other finasteride or dutasteride product is being used without supervision.
• The scalp is healthy.
• The user understands that finished-product synergy is unproven.
• The user will stop and report significant adverse effects.

Buyer Decision Flowchart

Confirmed androgenetic alopecia?

          │

     ┌────┴────┐

     │         │

    No        Yes

     │         │

Seek diagnosis  Has high-strength minoxidil

                plus finasteride been reviewed?

                       ┌────┴────┐

                      No        Yes

                       │          │

                 Medical review   Complete FR12

                                  label available?

                                      ┌────┴────┐

                                     No        Yes

                                      │          │

                               Do not start   Can twice-daily,

                                              four-hour routine

                                              be maintained?

                                                ┌────┴────┐

                                               No        Yes

                                                │          │

                                         Discuss another  Review transfer,

                                         format           fertility, PSA

                                                          and side effects

Final Verdict: What Does Alfatradiol Add to FR12?

In FR12 alfatradiol finasteride spray, alfatradiol provides an additional androgen-related ingredient beyond topical finasteride.

Its strongest evidence-safe role is:

Supporting possible stabilisation or deceleration of androgenetic hair loss.

Finasteride remains the more established DHT-targeting component, with stronger evidence in male-pattern hair loss.

The combination should therefore be described as:

• A multi-active formula containing two androgen-related ingredients.
• A product designed around both stimulation and DHT support.
• A clinically plausible formulation concept.
• A product requiring medical and label verification.

It should not be described as:

• Proven dual DHT blocking.
• Twice as effective.
• Synergistic.
• Free of systemic exposure.
• Safer than oral finasteride.
• Suitable for every man.
• Proven to outperform FR10, FIN25 or another treatment.

The direct clinical evidence is strongest for topical finasteride as a treatment class. Alfatradiol evidence suggests stabilisation, but much of the research involves women and 0.025% formulations. No FR12 trial establishes the contribution of each ingredient or their combined effect.

Review the live Follics FR12 Minoxidil 12% and Finasteride Spray page and compare it with the physical packaging before first use.

Readers comparing different formulation strategies can review:

• Regrowth Labs FIN25 topical finasteride solution
• Follics FR10 Minoxidil 10% treatment
• The broader Follics hair-loss product range
• Other men’s hair-care products available in the UAE
• The complete range of hair-loss treatments available in the UAE

For current product support and ordering questions, review the Hims & Hers UAE FAQs.

For missing finasteride or alfatradiol concentrations, damaged packaging, unexpected reactions or website-to-label discrepancies, contact Hims & Hers UAE before continuing treatment.

Frequently Asked Questions

What is FR12?

FR12 is a topical Follics spray containing 12% Minoxidil Sulphate, Finasteride USP, alfatradiol and several supporting ingredients. It is positioned for vertex and hairline thinning.

Why does FR12 contain both alfatradiol and finasteride?

Both ingredients are included within the formula’s androgen and DHT-support strategy. Finasteride directly inhibits 5-alpha-reductase, while alfatradiol has been studied mainly for slowing or stabilising androgenetic hair loss.

Is alfatradiol the same as finasteride?

No. They are different substances with different evidence bases. Finasteride has stronger evidence for direct 5-alpha-reductase inhibition and male-pattern hair loss.

Is alfatradiol an estrogen?

Alfatradiol is 17α-estradiol, a structural form of estradiol. It should not be described as biologically inactive or automatically hormone-free.

Does alfatradiol regrow hair?

Clinical evidence is mixed. Controlled research has more clearly supported slowing or stabilising hair loss than producing substantial new growth.

Has alfatradiol been studied in men?

Some older studies included mixed populations, but much of the more detailed modern evidence involves women. Its specific contribution to FR12 in men is not established.

Is the combination of alfatradiol and finasteride clinically proven?

No FR12-specific trial demonstrating additive or synergistic benefit was identified.

What is the finasteride concentration in FR12?

The public product page lists Finasteride USP but does not state its percentage. Check the physical bottle or request manufacturer confirmation.

What is the alfatradiol concentration in FR12?

The public page does not state the alfatradiol percentage. This must be confirmed before publishing concentration-specific claims.

How many pumps of FR12 should be used?

The official page directs users to dispense five pumps per application, twice daily.

How long should FR12 remain on the scalp?

The product page states four or more hours.

Does topical FR12 have zero systemic absorption?

No such claim is supported. Topical finasteride formulations can produce measurable systemic exposure and serum-DHT reduction.

Can FR12 cause finasteride-related side effects?

Systemic effects cannot be ruled out. Users should report sexual, mood, breast or reproductive symptoms to a qualified clinician.

Should FR12 users mention treatment before a PSA test?

Yes. FR12 contains finasteride, and topical finasteride can have systemic effects. Treatment should be disclosed before PSA interpretation.

Can pregnant women touch FR12?

Pregnant or potentially pregnant individuals should avoid contact with the wet finasteride-containing solution. Exposed skin should be washed promptly with soap and water.

Can FR12 be used with oral finasteride?

Do not combine them without a qualified clinician reviewing total finasteride exposure and risks.

Can FR12 be used with FIN25?

Do not layer two topical finasteride products unless specifically prescribed and monitored.

Can FR12 be combined with dutasteride?

Do not combine finasteride and dutasteride products independently.

Is FR12 stronger than FR10?

FR12 lists a higher minoxidil-sulphate percentage and contains finasteride and alfatradiol, but those differences do not prove that it is more effective or suitable for a particular person.

Is FR12 suitable for a first-time minoxidil user?

A 12% multi-active formula should not automatically be treated as a starting option. Diagnosis, lower-strength options, heart history, scalp tolerance and treatment routine should be medically reviewed.

Can women use FR12?

FR12 is currently listed in the Men category. Finasteride creates major pregnancy-related concerns, and use in women requires specialist assessment rather than self-selection.

Can FR12 be applied after microneedling?

Do not apply it over freshly microneedled, bleeding or damaged scalp unless a qualified clinician has prescribed a specific protocol.

What should I do if FR12 irritates my scalp?

Stop application and seek advice when redness, burning, itching, scaling or swelling persists or worsens.

How should FR12 be stored in the UAE?

Keep it in a cool, dry place away from direct sunlight, freezing and excessive heat. Do not leave it in a parked vehicle.